Nimoli Pharmaceuticals (P) Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 14-12-2024
- Paid Up Capital ₹ 2.60 M
as on 14-12-2024
- Company Age 26 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.11 Cr
as on 14-12-2024
- Revenue 12.34%
(FY 2022)
- Profit 25.38%
(FY 2022)
- Ebitda -33.75%
(FY 2022)
- Net Worth 7.44%
(FY 2022)
- Total Assets -1.47%
(FY 2022)
About Nimoli Pharmaceuticals (P)
The Corporate was formerly known as Nimoli Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 2.60 M.
The company has closed loans amounting to ₹1.11 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Vimla Sharma, Vinod Sharma, and Sudesh Bansal serve as directors at the Company.
- CIN/LLPIN
U24232DL1998PTC361925
- Company No.
033999
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Aug 1998
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Nimoli Pharmaceuticals (P)?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vimla Sharma  | Director | 16-Aug-2005 | Current |
| Vinod Sharma | Director | 04-Aug-1998 | Current |
| Sudesh Bansal | Director | 16-Aug-2005 | Current |
Financial Performance of Nimoli Pharmaceuticals (P).
Nimoli Pharmaceuticals (P) Ltd., for the financial year ended 2022, experienced significant growth in revenue, with a 12.34% increase. The company also saw a substantial improvement in profitability, with a 25.38% increase in profit. The company's net worth moved up by a moderate rise of 7.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nimoli Pharmaceuticals (P)?
In 2020, Nimoli Pharmaceuticals (P) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 19 Jun 2017 | ₹7.50 M | Satisfied |
Icici Bank Limited Creation Date: 13 Jan 2011 | ₹3.55 M | Satisfied |
How Many Employees Work at Nimoli Pharmaceuticals (P)?
Nimoli Pharmaceuticals (P) has a workforce of 22 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nimoli Pharmaceuticals (P), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nimoli Pharmaceuticals (P)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
